🇺🇸 Fentanyl and bupivacaine in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 11

Most-reported reactions

1. Hypoaesthesia — 2 reports (18.18%)
2. Anxiety — 1 report (9.09%)
3. Dyspnoea — 1 report (9.09%)
4. Foetal Heart Rate Deceleration Abnormality — 1 report (9.09%)
5. Guillain-Barre Syndrome — 1 report (9.09%)
6. Idiosyncratic Drug Reaction — 1 report (9.09%)
7. Paraesthesia — 1 report (9.09%)
8. Paraplegia — 1 report (9.09%)
9. Product Label Issue — 1 report (9.09%)
10. Sensory Loss — 1 report (9.09%)

Source database →

Frequently asked questions

Is Fentanyl and bupivacaine approved in United States?

Fentanyl and bupivacaine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Fentanyl and bupivacaine in United States?

Hospital Central Dr. Luis Ortega is the originator. The local marketing authorisation holder may differ — check the official source linked above.